Combined Use of eGFR and UACR for Kidney Assessment in Type 2 Diabetes

Definitions and Distinctions

UACR detects albuminuria, indicating kidney damage rather than filtration function – the ratio reflects increased glomerular permeability. 3
Albuminuria is an early marker of diabetic kidney disease and independently predicts progression to end‑stage kidney disease and cardiovascular events. 4
Normal UACR is defined as < 30 mg/g creatinine in spot urine samples. 4
eGFR quantifies the kidneys’ filtration capacity and therefore represents true kidney function. 3
The 2021 CKD‑EPI equation without a race coefficient is the preferred method for calculating eGFR. 5
An eGFR < 60 mL/min/1.73 m² defines CKD stages 3–5. 3

Both eGFR and albuminuria must be measured together to stage CKD, guide therapeutic decisions, and assess cardiovascular risk (clinical guideline recommendation). 3
Regardless of eGFR level, higher albuminuria independently predicts CKD progression, cardiovascular disease, and mortality (strong prognostic evidence). 8
Patients with type 2 diabetes frequently exhibit discordant patterns: reduced eGFR without albuminuria or albuminuria with preserved eGFR. 4
The prevalence of reduced eGFR without albuminuria is rising as diabetes becomes more common. 4
Unlike type 1 diabetes, many individuals with type 2 diabetes present with CKD at the time of diabetes diagnosis. 3

Measure spot UACR and eGFR annually beginning at the diagnosis of type 2 diabetes (screening guideline). 1
Prefer a first‑morning void urine sample to minimize pre‑analytical variability. 5
Confirm an abnormal UACR with ≥ 2 of 3 specimens collected over 3–6 months because of > 20 % biological variability. 3
Transient factors such as recent exercise, infection, fever, congestive heart failure, marked hyperglycemia, menstruation, or severe hypertension can falsely raise UACR and should be excluded before confirming persistent albuminuria. 4

The KDIGO classification system integrates eGFR stages (G1‑G5) and albuminuria categories (A1‑A3) into a comprehensive risk matrix (guideline recommendation). 4
Higher albuminuria categories (A2: 30‑299 mg/g; A3: ≥ 300 mg/g) combined with lower eGFR stages markedly increase the risk of kidney failure and cardiovascular events. 4
ACE inhibitors or ARBs are recommended for patients with UACR 30‑299 mg/g (moderate recommendation) and strongly recommended for UACR ≥ 300 mg/g or eGFR < 60 mL/min/1.73 m² (strong recommendation). 3
SGLT2 inhibitors and GLP‑1 receptor agonists with proven renal benefit should be considered based on the presence of albuminuria and the eGFR level (evidence‑based recommendation). 2
Non‑steroidal mineralocorticoid receptor antagonists are advised for patients with eGFR ≥ 25 mL/min/1.73 m² and UACR ≥ 30 mg/g. 2

When eGFR < 60 mL/min/1.73 m² and/or UACR > 30 mg/g, re‑measure both parameters every 6 months (moderate‑strength recommendation). 6
As CKD stage advances, increase monitoring frequency to 1‑4 times per year. 1

Adding cystatin C to creatinine improves eGFR accuracy, reduces racial/ethnic bias, and is useful for confirmatory testing when creatinine‑based eGFR is uncertain (guideline endorsement). 5
Cystatin C should be considered in individuals with low muscle mass or when treatment decisions require precise GFR estimation. 5
Cystatin C may detect kidney dysfunction earlier than creatinine in people with diabetes. 5
Within‑individual UACR variability is high (coefficient of variation ≈ 48.8 %); therefore, 2 of 3 abnormal specimens are required for a reliable diagnosis (methodological recommendation). 3

Refer patients to a nephrologist when eGFR falls below 30 mL/min/1.73 m² (strong recommendation). 3
Prompt referral is also warranted for unclear kidney disease etiology, rapidly progressive kidney dysfunction, or complex management issues. 3
Atypical features—such as active urinary sediment, rapidly rising albuminuria, swiftly declining eGFR, or absence of retinopathy in type 1 diabetes—should trigger nephrology referral. 3